印度的PMBJP计划通过16,900个中心和在线平台,扩大人们获得负担得起的优质非专利药品的机会,将药品成本削减90%,并节省30,000克朗。 India’s PMBJP program expands access to affordable, quality generic drugs through 16,900 centers and online platforms, cutting drug costs by up to 90% and saving ₹30,000 crore.

印度政府的Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana(PMBJP)通过超过16,900个中心和在线平台,扩大人们获得负担得起的非专利药品的机会,提供的价格比品牌版本低90%的药品。 The Indian government’s Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana (PMBJP) expands access to affordable generic medicines through over 16,900 centers and online platforms, offering drugs at up to 90% lower prices than branded versions. 这些非专利药物符合严格的质量和安全标准,包括生物等效测试,确保与品牌药品相同。 These generics meet strict quality and safety standards, including bioequivalence testing, ensuring they work the same as brand-name drugs. 该方案在过去10年中节省了约30 000格朗,将自费保健支出从62.6%减少到39.4%。 The program has saved an estimated ₹30,000 crore over the past decade and reduced out-of-pocket health spending from 62.6% to 39.4%. 敦促患者在切换前核实活性成分、强度、剂量形式和释放类型,并咨询保健提供者。 Patients are urged to verify active ingredients, strength, dosage form, and release type before switching and to consult healthcare providers. 医生现在必须在大写字母中写上通用名词,以提高清晰度和促进知情选择。 Doctors must now write generic names in capital letters to improve clarity and promote informed choices.